Previous 10 | Next 10 |
ProQR press release ( NASDAQ: PRQR ): Q3 GAAP EPS of -€0.34. Revenue of €0.96M (+10.3% Y/Y). For further details see: ProQR GAAP EPS of -€0.34, revenue of €0.96M
Development of Axiomer ® RNA base editing technology platform continues across multiple therapeutic areas; initial pipeline targets to be disclosed in early 2023 with Analyst and Investor R&D event to be held in Q1 2023 Management Team appointments and planned additions t...
LEIDEN, Netherlands & CAMBRIDGE, Mass., Nov. 03, 2022 (GLOBE NEWSWIRE) -- LEIDEN, Netherlands & CAMBRIDGE, Mass., November 3, 2022 -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a company dedicated to changing lives through the creation of transformative RN...
Raymond James has upgraded ProQR Therapeutics N.V. ( NASDAQ: PRQR ) to Outperform from Market Perform after the Dutch biotech announced on Thursday a decision to focus on its Axiomer RNA- editing technology platform exclusively. The upgrade is “based on high convi...
Dutch biotech ProQR Therapeutics N.V. ( NASDAQ: PRQR ) announced on Thursday that the European Medicines Agency (EMA) recommended an additional pivotal clinical trial before submitting a marketing application for the company’s lead candidate sepofarsen. An investiga...
In line with corporate strategy update in April, ProQR to focus exclusively on the development of the Axiomer ® RNA editing technology platform across multiple therapeutic areas; update on initial pipeline targets expected in late 2022/early 2023 Additional pivotal trial reco...
ProQR press release ( NASDAQ: PRQR ): Q2 GAAP EPS of -€0.21 beats by €0.02 . Revenue of €1.02M (+325.0% Y/Y) beats by €0.07M . For further details see: ProQR GAAP EPS of -$0.21 beats by €0.02, revenue of €1.0...
ProQR is accelerating the development of its Axiomer ® RNA base-editing technology platform across multiple therapeutic areas and will provide an update on first targets in H2 2022 Company plans to discuss findings from sepofarsen Illuminate trial with regulators and prov...
LEIDEN, Netherlands & CAMBRIDGE, Mass., June 28, 2022 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a company dedicated to changing lives through the creation of transformative RNA therapies, today announced that Company management will partic...
Annual General Meeting of Shareholders to be held on June 30, 2022 René Beukema joins management team as Chief Corporate Development Officer and General Counsel and is nominated to Management Board Gerard Platenburg to assume Chief Scientific Officer role, with leadership ove...
News, Short Squeeze, Breakout and More Instantly...
ProQR Therapeutics N.V. Company Name:
PRQR Stock Symbol:
NASDAQ Market:
ProQR Therapeutics N.V. Website:
LEIDEN, Netherlands & CAMBRIDGE, Mass., June 18, 2024 (GLOBE NEWSWIRE) -- ProQR Therapeutics NV (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies, today announced it will participate in the RNA Editing Summit, June 18-20, 2024, in Boston, Massa...
Preclinical proof of concept data for the AX-0810 program targeting NTCP for cholestatic diseases presented at ASGCT 27 th Annual Meeting – Management to host webinar today at 8:00 am EDT to highlight data Martin Maier, PhD nominated to Board with Annual General Meeting scheduled f...
ProQR scientists report for the first time in the ADAR RNA editing field in vivo proof of target engagement (RNA editing) leading to meaningful changes in biomarkers in NHPs using Axiomer™ RNA Editing Oligonucleotides Preclinical proof of concept for the Company’s AX-0810 pr...